Literature DB >> 28692538

Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-monoinfected patients.

Maud Lemoine1, Karine Lacombe, Jean P Bastard, Manuela Sébire, Laurent Fonquernie, Nadia Valin, Soraya Fellahi, Jacqueline Capeau, Pierre-Marie Girard, Jean-Luc Meynard.   

Abstract

BACKGROUND: Metabolic syndrome (MetS) and nonalcoholic fatty liver disease have become a common finding in HIV-infected patients. However, the severity, risk factors and pathogenesis of liver fibrosis in this population have been poorly documented.
OBJECTIVES: To assess the impact of MetS on liver fibrosis and analyze the association between MetS, liver fibrosis and markers of adipose tissue and macrophage activation.
METHODS: In a matched cohort of HIV-1-monoinfected patients with and without MetS, after exclusion of other causes of liver disease, we assessed liver stiffness measurement and measured levels of serum adipokines, homeostasis model assessment index and soluble CD163 (sCD163) and CD14 as markers of fat, insulin resistance and macrophage/monocyte activation, respectively.
RESULTS: A total of 468 HIV-monoinfected individuals were enrolled; 405 (203 with MetS/202 without MetS) were analyzed. Patients with MetS were older and 49% had insulin resistance. The prevalence of significant liver fibrosis (≥F2) was higher in patients with MetS [25.1%, 95% confidence interval (19.3-31.2)] compared with those without MetS [7.9%, (4.6-12.5), P < 0.0001]. In multivariate analysis with adjustment on MetS, obesity [odds ratio: 3.0 (1.1-8.4)] and homeostasis model assessment [1.1 (1.007-1.2)] were independent factors of advanced fibrosis (>= F3).. Serum levels of adipokines and sCD163 were significantly associated with the degree of liver fibrosis. When adjusted on MetS, leptin and sCD163 remained strongly associated with fibrosis/cirrhosis, whereas HIV parameters and antiretroviral therapy were not.
CONCLUSION: In HIV-monoinfected patients, MetS is an important risk factor of liver fibrosis. Adipose tissue and macrophage activation might be key players in the development of liver fibrosis but the exact mechanisms need to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28692538     DOI: 10.1097/QAD.0000000000001587

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  13 in total

1.  Liver-related Events in Human Immunodeficiency Virus-infected Persons With Occult Cirrhosis.

Authors:  Amine Benmassaoud; Roy Nitulescu; Thomas Pembroke; Alex S Halme; Peter Ghali; Marc Deschenes; Philip Wong; Marina B Klein; Giada Sebastiani
Journal:  Clin Infect Dis       Date:  2019-09-27       Impact factor: 9.079

2.  Obesity and Fat Metabolism in Human Immunodeficiency Virus-Infected Individuals: Immunopathogenic Mechanisms and Clinical Implications.

Authors:  Catherine Godfrey; Andrew Bremer; Diana Alba; Caroline Apovian; John R Koethe; Suneil Koliwad; Dorothy Lewis; Janet Lo; Grace A McComsey; Allison Eckard; Suman Srinivasa; Janine Trevillyan; Clovis Palmer; Steven Grinspoon
Journal:  J Infect Dis       Date:  2019-07-02       Impact factor: 5.226

3.  Sex Differences, Cocaine Use, and Liver Fibrosis Among African Americans in the Miami Adult Studies on HIV Cohort.

Authors:  Gustavo Zarini; Sabrina Sales Martinez; Adriana Campa; Kenneth Sherman; Javier Tamargo; Jacqueline Hernandez Boyer; Colby Teeman; Angelique Johnson; Abraham Degarege; Pedro Greer; Qingyun Liu; Yongjun Huang; Raul Mandler; David Choi; Marianna K Baum
Journal:  J Womens Health (Larchmt)       Date:  2020-01-31       Impact factor: 2.681

4.  FIB-4 index-based surveillance for advanced liver fibrosis in diabetes patients.

Authors:  Nozomi Kawata; Hirokazu Takahashi; Shinji Iwane; Kanako Inoue; Motoyasu Kojima; Michiko Kohno; Kenichi Tanaka; Hitoe Mori; Hiroshi Isoda; Satoshi Oeda; Yayoi Matsuda; Yoshiaki Egashira; Jyunichi Nojiri; Hiroyuki Irie; Yuichiro Eguchi; Keizo Anzai
Journal:  Diabetol Int       Date:  2020-07-09

5.  Increased Body Mass Index and Type 2 Diabetes Are the Main Predictors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Liver Biopsies of Patients With Human Immunodeficiency Virus Monoinfection.

Authors:  James B Maurice; Robert Goldin; Andrew Hall; Jennifer C Price; Giada Sebastiani; Caryn G Morse; Laura Iogna Prat; Hugo Perazzo; Lucy Garvey; Patrick Ingiliz; Giovanni Guaraldi; Emmanouil Tsochatzis; Maud Lemoine
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 9.079

6.  Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease.

Authors:  Lindsay T Fourman; Takara L Stanley; Isabel Zheng; Chelsea S Pan; Meghan N Feldpausch; Julia Purdy; Julia Aepfelbacher; Colleen Buckless; Andrew Tsao; Kathleen E Corey; Raymond T Chung; Martin Torriani; David E Kleiner; Colleen M Hadigan; Steven K Grinspoon
Journal:  Clin Infect Dis       Date:  2021-06-15       Impact factor: 9.079

Review 7.  Using Zebrafish as a Disease Model to Study Fibrotic Disease.

Authors:  Xixin Wang; Daniëlle Copmans; Peter A M de Witte
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

Review 8.  Contribution of Adipose Tissue to the Chronic Immune Activation and Inflammation Associated With HIV Infection and Its Treatment.

Authors:  Christine Bourgeois; Jennifer Gorwood; Anaelle Olivo; Laura Le Pelletier; Jacqueline Capeau; Olivier Lambotte; Véronique Béréziat; Claire Lagathu
Journal:  Front Immunol       Date:  2021-06-18       Impact factor: 7.561

9.  Highlights from the 9th IAS Conference on HIV Science, 23-26 July 2017, Paris, France.

Authors:  Christina K Psomas; Tristan J Barber; Sofie Rutsaert; Sabine Kinloch-de Loës
Journal:  J Virus Erad       Date:  2017-10-01

10.  Significant Association of Aldosterone and Liver Fat Among HIV-Infected Individuals With Metabolic Dysregulation.

Authors:  Suman Srinivasa; Kathleen V Fitch; Nabiha Quadri; Patrick Maehler; Timothy K O'Malley; Edgar L Martinez-Salazar; Tricia H Burdo; Meghan Feldpausch; Martin Torriani; Gail K Adler; Steven K Grinspoon
Journal:  J Endocr Soc       Date:  2018-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.